MGMT promoter methylation associated with improved survival for patients with WHO Grade II Gliomas

(NRG Oncology) Further exploration into the endpoints of the NRGOncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and treatment regimen.